Merck KGaA: avelumab antibody fails gastric cancer study.
(CercleFinance.com) - Merck KGaA and its US partner Pfizer said on Wednesday that their Phase III trial on avelumab did not meet its primary endpoint of superior overall survival in patients with advanced gastric cancer.
In practice, the trial, which enrolled 371 patients from 147 sites in Asia, Australia, Europe, North America and South America did not meet its primary endpoint of superior overall survival compared with chemotherapy.
Gastric cancer is the third most common cause of cancer death globally.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In practice, the trial, which enrolled 371 patients from 147 sites in Asia, Australia, Europe, North America and South America did not meet its primary endpoint of superior overall survival compared with chemotherapy.
Gastric cancer is the third most common cause of cancer death globally.
Copyright (c) 2017 CercleFinance.com. All rights reserved.